Pneumocystis carinii infection in non-AIDS patients

Current Opinion in Infectious Diseases

Volumn 12, Issue 4, 1999, Pages 371-377

  Miller, Robert F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; FOLINIC ACID; GLUCOCORTICOID; MALOPRIM; PENTAMIDINE; PRIMAQUINE; PYRIMETHAMINE; TRIMETHOPRIM; TRIMETREXATE;

DISEASE TRANSMISSION; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 0032872790     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199908000-00011     Document Type: Review

References (59)

1. Hughes WT. Prologue to AIDS. The recognition of infectious opportunists. Medicine 1998; 77:227-232. An historical account of the discovery of P carinii and the development of a knowledge base about its role before AIDS.
2. Day J, Williams IG, Zumla A, Miller RF. Protection from Pneumocystis carinii pneumonia. Sex Trans Infect 1999; 75:202-203.
3. Sepkowitz KA, Brown AE, Telzak EE, Gottleib S, Armstrong D, Pneumocystis carinii pneumonia among patients without AIDS at a Cancer hospital. JAMA 1992; 267:832-837.
4. Arend SM, Kroon FP, Van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. Arch Intern Med 1995; 155:2436-2441.
5. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 1996; 71:5-13.
6. Benfield TL, Prento P, Junge J, Vestbo J, Lundgren JD. Alveolar damage in AIDS-associated Pneumocystis carinii pneumonia. Chest 1997; 111:1193-1197.
7. Benfield TL, Lundgren JD. The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. FEMS Immunol Med Microbiol 1998; 22:129-134. This article forms part of a special issue, which brings together many articles detailing current knowledge of the molecular biology of P. carinii and the pathogenesis of P. carinii pneumonia.
8. Garbe TR, Stringer JR. Molecular characterisation of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii. Infect Immun 1994; 62:3092-3101.
9. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997; 99:2110-2117.
10. Koziel H, Eeichbaum Q, Kruskal BA, Pinkston P, Rogers RA, Armstrong MYK, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor down-regulation. J Clin Invest 1998; 102:1332-1344. Impaired alveolar macrophage mannose receptor-mediated binding/phagocytosis of P. carinii occurs in HIV infection and may contribute to the susceptibility of HIV-infected persons to P. carinii pneumonia.
11. Hanano R, Reifenberg K, Kaufman SHE. Activated pulmonary macrophages are insufficient for resistance against Pneumocystis carinii. Infect Immunol 1998; 66:305-314.
12. Theus SA, Linke MJ, Andrews RP, Walzer PD. Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii. Infect Immun 1993; 61:4703-4709.
13. Theus SA, Sawhney N, Smulian AG, Walzer PD. Proliferative and cytokine responses of human T-lymphocytes isolated from human immunodeficiency virus-infected patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 1998; 177:238-241.
14. Jensen T, Aliouat ELM, Lundgren B, Settnes OP, Karlsson A, Dahlgren C, et al. Cultured rat and purified human Pneumocystis carinii stimulate intra- but not extracellular free radical production in human neutrophils. J Euk Microbiol 1998; 45:544-547.
15. Prevost M-C, Escamilla R, Aliouat ELM, Cere N, Coudert P, Dei-Cas E. Pneumocystis pathophysiology. FEMS Immunol Med Microbiol 1998; 22:123-128. A detailed account of the changes in pulmonary surfactant that occur in response to P. carinii infection.
16. Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunisation with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 1998; 16:1149-1157. This study showed that immunized rats had improved survival and a lower organism burden.
17. Wakefield AE. Genetic heterogeneity in Pneumocystis carinii: an introduction. FEMS Immunol Med Microbiol 1998; 22:5-13. An overview of the molecular biological data confirming genetic heterogeneity in P. carinii from different host species.
18. Stringer JR, Walzer PD. Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS. AIDS 1996; 10:561-571.
19. Wakefield AE. Genetic heterogeneity in human-derived Pneumocystis carinii. FEMS Immunol Med Microbiol 1998; 22:59-65. The genetic heterogeneity of P. carinii in man is reviewed.
20. Lee C-H, Helweg-Larsen J, Tang X, Jin S, Li B, Bartlett MS, et al. Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol 1998; 36:734-741. Typing of samples of P. carinii from nine countries typed using ITS reveals 59 different types of human P. carinii.
21. Latouche S, Ortona E, Mazars E, Margutti P, Tamburrini E, Siracursano A, et al. Biodiversity of Pneumocystis carinii hominis: typing with different DNA regions. J Clin Microbiol 1997; 35:383-387.
22. Tsolaki AG, Beckers P, Wakefield AE. Pre-AIDS era isolates of Pneumocystis carinii f. sp. hominis: high genotypic similarity with contemporary isolates. J Clin Microbiol 1998; 36:90-93. Typing of P. carinii at four loci reveals genetic similarity between isolates from before the AIDS pandemic and current samples from HIV-infected patients.
23. Helweg-Larsen J, Tsolaki AG, Miller RF, Luedgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. Q J Med 1988; 91:813-820. First report of genotyping of isolates from three case clusters of P. carinii pneumonia demonstrates the low frequency of person-to-person transmission of infection. Reviews previous reports of case clusters.
24. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 1996; 34:1754-1759.
25. Olsson M, Lidman C, Latouche S, Bjorkman A, Roux P, Linder E, et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998; 36:1737-1740. The finding of P. carinii DNA identified by PCR in the air of hospital environments strengthens the possibility of the acquisition of P. carinii from the environment.
26. Varela JM, Dapena J, Regordan C, Blanco M, Gonzalez de la Puente MA, Calderon EJ. Absence of Pneumocystis carinii carriers among patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998; 17:741-742.
27. Armbruster C, Hassl A, Kriwanek S. Pneumocystis carinii colonization in the absence of immunosuppression. Scand J Infect Dis 1997; 29:591-593.
28. Nevez G, Raccurt C, Jounicaux V, Dei-Cas E, Mazars E. Pneumocystis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS 1999; 13:535-536. P. carinii may colonize the lungs of mildly/moderately immunosuppressed patients and act as a potential reservoir for infection.
29. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch Intern Med 1995; 155:1125-1128.
30. Hughes WT, Feldman S, Aur RJA, Verzoza MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36:2004-2009.
31. Hardy AM, Wajszcuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii pneumonia in renal transplant patients treated with cyclosporine and steroids. J Infect Dis 1984; 149:143-147.
32. Morrison VA. The infectious complications of chronic lymphocytic leukaemia. Semin Oncol 1998; 25:98-106.
33. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997; 25:215-218.
34. Duncan KO, Imaeda S, Milstone LM. Pneumocystis carinii complicating methotrexate treatment of pityriasis rubra pilaris. J Am Acad Dermatol 1998; 39:276-278. Methotrexate-induced lymphopenia is probably responsible for increased susceptibility to P. carinii.
35. Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Am J Respir Crit Care Med 1997; 155:60-66.
36. Walzer PD. Editorial response: Pneumocystis carinii pneumonia in patients without human immunodeficiency virus infection. Clin Infect Dis 1997; 25:219-220.
37. Tattevin P, Di Palma M, Vittecoq D. Pneumocystis carinii pneumonia in patients with breast cancer: are there contributing local factors? Clin Infect Dis 1998; 26:1018-1019.
38. Cisneros JM, Munoz P, Torre-Cisneros J, Gurgui M, Rodriguez-Hernandez MJ, Aguado JM, et al. Pneumonia after heart transplantation: a multi-institutional study. Clin Infect Dis 1998; 27:324-331. P. carinii pneumonia only developed in those who did not take prophylaxis.
39. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 1996; 71:102-103.
40. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995-1004. A review of the currently available regimens for prophylaxis.
41. Hughes WT, Kuhn S, Chaudhary S. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1997; 297:1419-1426.
42. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998; 27:191-204. An overview of studies of dapsone for prophylaxis in HIV infection.
43. Machado CM, Macedo MCA, Medeiros RSS, Massumoto C, Silva ACM, Castelli JB, et al. Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation. Acta Haematol 1998; 99:54-56. Bone marrow recipients with T. gondii antibodies given nebulized pentamidine prophylaxis were at risk of developing toxoplasmosis.
44. Wulf GG, Reichard U, Wormann B, Hiddemann W. Pneumocystis carinii pneumonia with peripheral modular infiltrates in a patient with T-acute lymphoblastic leukaemia. J Clin Oncol 1998; 16:3476-3477.
45. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Ann Intern Med 1974; 80:83-93.
46. Tuncer S, Erguven S, Kocagoz S, Unal S. Comparison of cytochemical staining, immunoflourescence and PCR for diagnosis of Pneumocystis carinii on sputum samples. Scand J Infect Dis 1998; 30:125-128. PCR on non-invasive respiratory samples may be useful for diagnosis.
47. Wakefield AE, Miller RF, Guiver LA, Hopkin JM. Oropharyngeal samples for detection of Pneumocystis carinii by DNA amplification. Q J Med 1993; 86:401-406.
48. Helweg-Larsen J, Skov Jensen J, Benfield T, Gerner Svendsen UJ, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 1998; 36:2068-2072. PCR on saline mouthwash had a sensitivity of 89% and a negative predictive value of 91% for diagnosis of P. carinii (in comparison, PCR on BAL had a sensitivity of 100% and negative predictive value of 100%).
49. Atzori C, Agostini F, Angeli E, Mainini A, Orlando G, Cargnel A. Combined use of blood and oropharyngeal samples for non-invasive diagnosis of Pneumocystis carinii pneumonia using the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 1998; 17:241-246. PCR on saline mouthwash has a sensitivity of 78.5% and serum 71.4% sensitivity for diagnosis of P. carinii pneumonia.
50. Lundgren S, Wakefield AE. PCR for detecting Pneumocystis carinii in clinical or environmental samples. FEMS Immunol Med Microbiol 1998; 21:97-101. P. carinii may be detected in specimens containing low numbers of organisms in which conventional detection methods are insufficient.
51. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309-1314. A review of treatment regimens for P. carinii pneumonia.
52. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113:1215-1224. Although survival was not improved, surviving patients who received increased glucocorticoids had accelerated recovery as shown by a shorter duration of mechanical ventilation, intensive care unit stay and overall hospitalization.
53. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12:873-878. Non-synonymous mutations in the DHPS gene occur more frequently in immunosuppressed patients who have received sulpha/sulphone prophylaxis.
54. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 1998; 351:1631-1632. Mutations in the DHPS gene identified in patients failing co-trimoxazole treatment or prophylaxis suggests that drug resistance had developed.
55. Walker DJ, Wakefield AE, Dohn MN, Miller RF, Baughman RP, Hossler PA, et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis 1998; 178:1767-1775. Polymorphisms in the cytochrome b gene (the drug target of atovaquone) were found in patients failing atovaquone prophylaxis suggesting that drug resistance had developed.
56. Fufuta T, Muramatsu H, Fujie A, Fujihira S, Abdullah NR, Kojima S. Therapeutic effects of water-soluble echinocandin compounds on pneumocystisis pneumonia in mice. Antimicrob Agents Chemother 1998; 42:37-39.
57. Hall JE, Kerrigan JE, Ramachandran K, Bender BC, Stanko JP, Jones SK, et al. Anti-pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother 1998; 42:665-674.
58. Marreros E, Martinez CM, Almela MJ, Marriott MS, Heras FGD, Gargallo Viola D. Sordarins, in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis cannii and filamentous fungi. Antimicrob Agents Chemother 1998; 42:2863-2869.
59. Tsolaki AG, Miller RF, Wakefield AE. Oropharyngeal samples for genotyping and monitoring of response to treatment in AIDS patients with Pneumocystis carinii pneumonia. J Med Microbiol 1999 (in press).